Comprehensive Study Guide: Pharmacology, Medication Administration, Contrast Media, and Radiopharmaceuticals

Pharmacology Fundamentals and Nomenclature

  • Pharmacology Definition and Core Concepts

    • Pharmacology is the branch of science dedicated to the study of drugs, their biological actions, properties, interactions, and mechanisms within living systems.
    • Drugs are administered to produce specific therapeutic or diagnostic outcomes, but they also have the potential to produce adverse side effects, unwanted physiological effects, and allergic-type responses.
    • Pharmacists are specialized, state-licensed healthcare professionals specifically authorized to formulate, compound, prepare, and dispense medications upon receipt of an authorized practitioner's order.

  • Drug Naming Systems

    • Chemical Name: Describes the exact chemical structure and molecular composition of the compound.
    • Generic Name: The official, nonproprietary, standardized medical name assigned to a drug regardless of manufacturer.
    • Brand Name (Trade Name): The proprietary, commercial trademarked name assigned to a drug product by the specific pharmaceutical manufacturer producing and marketing it.
    • Drug Classification: The systematic grouping of medications categorized according to their primary chemical characteristics, mechanisms of action, or clinical therapeutic uses.

  • Controlled Substances and Regulatory Schedules

    • Controlled substances are classified into designated legal schedules based on their recognized medical utility, therapeutic indications, and their relative potential for abuse, dependence, or psychological and physiological misuse.
    • Schedule II Controlled Substances: Medications categorized in this schedule possess a currently accepted medical use in treatment in the United States, accompanied by a high potential for severe physical and psychological dependence and abuse.

  • Essential Pharmaceutical Classes and Exemplar Agents

    • Analgesic: A therapeutic substance that alleviates or relieves pain without inducing a concurrent loss of consciousness.
    • Antihistamine: An agent that antagonizes the action of histamine at receptor sites; used therapeutically to treat histamine-mediated allergic reactions and related systemic symptoms. Diphenhydramine (Benadryl) serves as a primary clinical example.
    • General Anesthetic: An agent that suppresses central nervous system activity to induce generalized loss of consciousness, sensation, and neuromuscular responsiveness. Propofol is a standard clinical general anesthetic agent.
    • Antiarrhythmic Agents: Medications administered in clinical emergency protocols to treat cardiac dysrhythmias and stabilize electrical conduction patterns within the myocardium.
    • Opioid Antagonists (Naloxone): A specific opioid receptor antagonist administered intravenously or parenterally to reverse opioid effects rapidly, particularly life-threatening opioid-induced central nervous system depression and respiratory depression.
    • Antidiabetic Agents (Metformin): An oral biguanide medication prescribed for glycemic control in patients with type 2 diabetes mellitus. Because of the risk of developing lactic acidosis in the presence of altered renal hemodynamics, it must be temporarily discontinued before and following examinations involving intravascular iodinated radiographic contrast agents.
    • Hematologic Iron Replacements (Ferumoxytol): A superparamagnetic iron oxide nanoparticle agent utilized in the clinical management of iron-deficiency anemia. Due to its magnetic susceptibility characteristics, circulating or stored ferumoxytol can transiently alter magnetic resonance imaging (MRI) tissue signal and appearance for up to 3 months3\,\text{months} following the final administered dose.

  • Continuum of Sedation and Airway Considerations

    • Sedation exists along a clinical continuum spanning minimal sedation (anxiolysis), moderate sedation (conscious sedation), deep sedation, and general anesthesia.
    • Deeper stages of sedation progressively diminish voluntary protective reflexes, verbal responsiveness, motor function, and the physiological capability to maintain independent airway patency and spontaneous ventilatory function.

Pharmacokinetics: ADME Principles

  • Overview of Pharmacokinetics

    • Pharmacokinetics describes the physiological disposition and journey of a drug within the body, defining what biological systems do to an administered chemical compound over time.
    • Memory Trick: ADME (Absorption→Distribution→Metabolism→Excretion\text{Absorption} \rightarrow \text{Distribution} \rightarrow \text{Metabolism} \rightarrow \text{Excretion}.

  • Stages of the ADME Continuum

    • Absorption: The primary biological process wherein an administered drug passes from its site of entry into the systemic bloodstream.
    • Distribution: The circulatory transport and delivery of the absorbed drug throughout the biological fluids, organs, vascular pathways, and target tissues of the body.
    • Metabolism (Biotransformation): The enzymatic alteration and biochemical modification of the original drug molecule into active, inactive, or water-soluble metabolites, predominantly executed by hepatic enzyme systems.
    • Excretion (Elimination): The definitive physiological processes through which the body purges, filters, and eliminates metabolic byproducts or parent drug molecules, predominantly occurring via renal filtration into urine, biliary/fecal pathways, pulmonary exhalation, or dermal secretions.

Medication Safety Protocols, Identification, and Orders

  • The Five Rights of Medication Administration

    • The Five Rights establish the fundamental standard of care and clinical safety check sequence required prior to administering any therapeutic agent.
    • Memory Trick: Remember the clinical sequence: drug, dose, patient, time, route.
    • Right Drug: Confirm that the correct pharmaceutical is selected; verify the drug label with precision against the clinical order multiple times during preparation and immediately before administration.
    • Right Dose: Verify that the measured amount matches the exact calculated volume, strength, and unit concentration ordered.
    • Right Patient: Validate patient identity using at least two institutional approved identifiers prior to giving any medication.
    • Right Time: Ensure the medication is administered at the prescribed time interval, frequency, or designated temporal sequence.
    • Right Route: Ensure delivery occurs via the ordered physiological pathway and anatomical method.

  • Positive Patient Identification Standards

    • Verification requires confirming the patient's identity through multiple simultaneous steps:
    • Inquire directly by asking the patient to state their full legal name and/or date of birth.
    • Cross-check the patient's active hospital identification wristband against the requisition or chart.
    • Confirm the intended type of medication to be administered against the validated identification.
    • Action Protocol for Identification Discrepancies: If a patient wristband exhibits incorrect patient details, the practitioner must stop the procedure, refrain from giving any medication, and accompany the patient to have a new armband fabricated with the accurate, validated patient information.

  • Medication Label Checks and Prescriber Orders

    • Under no circumstances may a drug be administered without an authorized physician's prescription or physician's order.
    • Inspect the drug packaging meticulously; never administer an unlabeled medication or a medication that has exceeded its stated manufacturer expiration date.
    • Strict documentation is legally mandated immediately following administration, recording the exact agent, dose, route, date, time, site, and observing practitioner signature.

  • Standard Medical Prescribing and Administration Abbreviations

    • PO\text{PO}: Per os (by mouth / oral route)
    • IM\text{IM}: Intramuscular (injected directly into muscle tissue)
    • IV\text{IV}: Intravenous (injected directly into venous vasculature)
    • SC / Subcut\text{SC / Subcut}: Subcutaneous (injected into the adipose tissue beneath the dermis)
    • ID\text{ID}: Intradermal (injected into the dermal skin layer)
    • bid\text{bid}: Twice a day (bis in die)
    • tid\text{tid}: Three times a day (ter in die)
    • qid\text{qid}: Four times a day (quater in die)
    • q2h / q3h\text{q2h / q3h}: Every 2 hours2\,\text{hours} / Every 3 hours3\,\text{hours}
    • prn\text{prn}: As needed (pro re nata)
    • stat\text{stat}: Immediately / at once (statim)
    • ac\text{ac}: Before meals (ante cibum)
    • pc\text{pc}: After meals (post cibum)

Metric Units, Conversions, and Delivery Equipment

  • Metric Volume and Mass Equivalence

    • Volume measurement units routinely utilized in pharmaceutical prep include liters (L\text{L}, milliliters (mL\text{mL}, and cubic centimeters (cc\text{cc}.
    • 1 L=1,000 mL1\,\text{L} = 1{,}000\,\text{mL}
    • 1 mL=1 cc1\,\text{mL} = 1\,\text{cc} (identical volumetric equivalence)
    • 1,000 μg=1 mg1{,}000\,\mu\text{g} = 1\,\text{mg}
    • 1,000 mg=1 g1{,}000\,\text{mg} = 1\,\text{g}
    • 1,000 g=1 kg1{,}000\,\text{g} = 1\,\text{kg}
    • 1 kg≈2.2 lbs1\,\text{kg} \approx 2.2\,\text{lbs}

  • Structural Anatomy of Syringes and Needles

    • Syringe Components:
    • Barrel: Calibrated chamber that holds the therapeutic fluid.
    • Plunger: Movable piston inside the barrel that pulls or pushes fluid.
    • Tip: Distal aperture that connects securely to the needle assembly (e.g., Luer-Lok or slip tip).
    • Needle Components:
    • Hub: Base connector that attaches the needle to the syringe tip.
    • Shaft / Cannula: The elongated hollow metal tubular stem of the needle.
    • Bevel: The slanted, angled cutting surface at the distal needle tip designed to pierce tissues smoothly.
    • Ampules vs. Vials:
    • Ampule: A hermetically sealed, all-glass container typically holding a single drug dose; must be snapped open carefully.
    • Vial: A glass or plastic bottle with a rubber diaphragm stopper secured by a metal band, containing either single or multiple drug doses.
    • Disposal Protocols: All used needles, glass ampules, and syringes must be discarded immediately into designated, puncture-resistant, approved biohazard sharps containers without recapping.

  • Needle Gauge and Dimensional Principles

    • Needle diameter exhibits an inverse geometric relationship to its nominal gauge rating.
    • Core Principle: As the inner lumen diameter decreases, the nominal gauge number increases.
    • Memory Trick: Higher gauge number = smaller needle diameter; lower gauge number = larger needle diameter.

Routes of Administration and Venipuncture

  • Systemic Classification of Administration Routes

    • Oral (PO\text{PO}): Swallowed by the patient and absorbed systemically across the mucosal linings of the gastrointestinal (GI\text{GI}) tract.
    • Sublingual: Placed beneath the tongue for direct absorption through mucosal venous plexuses; bypasses the gastrointestinal tract and initial hepatic first-pass metabolism.
    • Buccal: Held against the inner mucosal surface of the cheek until dissolved and absorbed.
    • Rectal: Instilled directly into the rectum for local action or systemic vascular uptake.
    • Topical: Applied directly onto external skin surfaces or mucous membranes for localized effect.
    • Transdermal: Applied via specialized adhesive dermal patches; continuously delivers an active drug through the epidermal barrier directly into systemic microcirculation.
    • Parenteral: Delivery achieved by bypassing the gastrointestinal tract entirely, specifically denoting invasive administration routes utilizing sterile needles or catheters.

  • Parenteral Injection Routes, Anatomical Sites, and Insertion Angles

    • Intradermal (ID\text{ID}): Injection targeted directly into the upper vascular dermis; executed at a very shallow needle angle (≈10∘ to 15∘\approx 10^\circ \text{ to } 15^\circ), depending on clinical technique.
    • Subcutaneous (SC / Subcut\text{SC / Subcut}): Delivery into the loose adipose connective tissue immediately beneath the dermal skin layers; executed at an insertion angle of 45∘45^\circ or 90∘90^\circ, dictated by anatomical tissue thickness and needle length.
    • Intramuscular (IM\text{IM}): Injected directly into the deep belly of muscular structures; administered at a perpendicular 90∘90^\circ angle.
    • Intravenous (IV\text{IV}): Instilled directly into the lumen of a vein; the insertion angle depends upon the chosen venipuncture technique, vein depth, and needle type.

  • Comparative Pharmacokinetic Onset by Route

    • Oral: Slowest systemic absorption rate because the drug must traverse gastrointestinal transit and digestive barriers.
    • Subcutaneous: Exhibiting slower systemic vascular absorption relative to intramuscular injections due to lower adipose vascularity.
    • Intramuscular: Demonstrates more rapid systemic vascular uptake than subcutaneous routes because skeletal muscle possesses superior capillary vascularization.
    • Intravenous: Produces an instantaneous pharmacological onset because the chemical agent is delivered directly into the circulating blood volume.

  • Venipuncture Guidelines and Vascular Access

    • Aseptic Standards: Strict hand hygiene must be performed, clean work surfaces established, and sterile procedural technique maintained when assembling angiocaths or puncturing veins.
    • Angiocath Execution: When placing an angiocatheter, clean hands, apply skin antiseptics, and position clean equipment over non-contaminated prep zones.
    • Anatomical Veins for Peripheral Venipuncture:
    • Cephalic Vein: Located on the lateral aspect of the forearm and antecubital fossa; highly suitable for access and diagnostic contrast delivery.
    • Median Cubital Vein: Positioned centrally in the antecubital fossa; universally favored due to its stabilization and accessibility.
    • Basilic Vein: Positioned along the medial aspect of the forearm and antecubital fossa.

Intravenous Delivery, Infiltration, and Extravasation

  • Intravenous Administration Methods

    • IV Push (Bolus): Rapid introduction of a concentrated medication volume directly into the venous pathway over a short duration.
    • Drip Infusion: Gravity-fed or continuous administration of a calculated fluid volume containing medication, delivered steadily over an extended timeframe.
    • Electronic IV Pump / Controller: Programmable electromechanical device utilized to meter and strictly govern the hourly flow rate and infusion volume.

  • Infiltration versus Extravasation Pathology

    • Infiltration: Pathological leakage or dislodgement of non-vesicant, benign intravenous infusion fluid out of the venous vessel into the adjacent perivascular interstitial tissues.
    • Extravasation: Accidental perivascular leakage or displacement of a vesicant, hyperosmolar, corrosive, or potentially tissue-toxic compound into the surrounding anatomical interstitial tissues.
    • Memory Trick: Infiltration = fluid in tissue. Extravasation = potentially damaging solution in tissue.
    • Clinical Signs of Complications: Rapid onset of localized perivascular swelling, edema, pallor, localized cooling of the skin, pain, or localized tenderness.
    • Intervention Protocol: If localized discomfort, swelling, or blanched resistance signals infiltration or extravasation, immediately cease the infusion, withdraw or clamp the catheter per protocol, notify the clinical provider, and execute institutional mitigation steps.

Radiographic Contrast Media Fundamentals

  • Diagnostic Purpose and Image Contrast Dynamics

    • Contrast media are specialized pharmaceutical formulations introduced into physiological lumens, vascular spaces, or anatomical tracts to artificially enhance subject contrast between adjoining tissues having similar inherent densities.
    • Subject Contrast: The inherent differential attenuation of the X-ray beam manifested as variations in optical density between contiguous anatomical structures.
    • Low Subject Contrast: Radiographic representations displaying minimal structural density distinctions, rendering discrete organs or soft-tissue planes challenging to visually resolve.
    • Memory Trick: Contrast acts like a highlighter, accentuating indistinct anatomic structures.

  • Physical Principles of Positive and Negative Contrast Media

    • Memory Trick: Positive = white. Negative = dark.
    • Positive Contrast Media (Radiopaque):
    • Agents exhibiting high atomic numbers that absorb more incident X-ray photons via the photoelectric effect.
    • Significantly increases beam attenuation.
    • Image appearance: Demonstrates increased brightness, manifesting as lighter or radiopaque white zones on finished images.
    • Negative Contrast Media (Radiolucent):
    • Agents characterized by low atomic densities (such as ambient air, oxygen, or carbon dioxide gas).
    • Transmits more incident X-ray photons; decreases beam attenuation.
    • Image appearance: Demonstrates increased radiographic optical density, manifesting as darker or radiolucent shadows.
    • Commonly employed in single-contrast studies or combined with positive contrast media in double-contrast fluoroscopic examinations.

  • Barium Sulfate Properties and Clinical Protocols

    • Physicochemical Properties:
    • Positive, radiopaque contrast medium used predominantly to evaluate the gastrointestinal tract.
    • Barium has an atomic number of Z=56Z = 56.
    • Highly insoluble in water; cannot form true molecular solutions and must be prepared and agitated as an aqueous suspension.
    • Routes of Administration:
    • Oral: Ingested to perform upper gastrointestinal radiographic evaluations, barium swallows, and small bowel follow-through examinations.
    • Rectal: Administered retrograde via an enema tip to perform barium enema examinations of the large colon.
    • Complications:
    • Intestinal Perforation and Peritonitis: Extravasation of insoluble barium through a compromised bowel wall into the peritoneal or retroperitoneal cavity triggers severe chemical peritonitis, adhesions, and life-threatening shock.
    • Fluid Overload (Hypervolemia): Systemic fluid absorption or shifts induced by hypertonic bowel preparations or massive fluid enemas can compromise cardiovascular stability.
    • Pre-Procedural History Risk Screening:
    • History of active ulcerative colitis or diverticulitis (heightened bowel wall fragility).
    • Recent lower endoscopy with biopsy (increased risk of transmural perforation).
    • Active pregnancy.
    • Severe constipation, bowel obstruction, or active diarrhea.
    • Active nausea and persistent vomiting.
    • Mental confusion, dizziness, or documented inability to comprehend and execute procedural instructions.

Iodinated Contrast Media: Chemistry, Kinetics, and Risk Assessment

  • Chemical Structure and Osmolality Profiles

    • Osmolality Defined: The concentration of osmotically active dissolved solute particles present in a unit mass of solution (mOsm/kg\text{mOsm/kg}.
    • Ionic Contrast Media: Chemical formulations composed of iodinated tri-iodinated benzene rings with carboxyl groups that dissociate into two distinct electrically charged particles (an anion and a cation) when dissolved in solution. Consequently, ionic agents possess high osmolality relative to plasma, which pulls fluid out of extravascular spaces into circulating vascular beds.
    • Nonionic Contrast Media: Molecules engineered with non-ionizing hydrophilic structures that do not dissociate into charged ionic particles in solution. Nonionic agents possess lower osmolality than traditional ionic preparations.
    • Hydroxyl Groups: Abundant hydroxyl (-OH\text{-OH}) molecular side chains attached to nonionic iodinated benzene rings significantly improve overall water solubility while dampening biological cytotoxicity.
    • Nonionic, low-osmolality agents generally cause far fewer adverse physiological reactions and perturbations than hyperosmolar ionic formulations, although significant allergic-like risks still remain.
    • Memory Trick: Ionic = ions / splits into two particles. Nonionic = does not split the same way.

  • Pre-Administration Screening and Patient History

    • Radiologic technologists must evaluate pre-existing clinical risk parameters prior to intravenous iodinated contrast injection:
    • Documented prior adverse reactions to iodinated contrast media.
    • General medical history of allergies, atopic conditions, or active bronchial asthma.
    • Pre-existing renal insufficiency, compromised glomerular function, or elevated serum creatinine / blood urea nitrogen (BUN\text{BUN}) levels.
    • History of diabetes mellitus.
    • Significant cardiovascular disease, hypertension, or congestive heart failure.
    • Multiple myeloma, sickle cell disease, or active hypercoagulability states.
    • Current pregnancy status.
    • Concurrent nephrotoxic pharmaceutical usage.
    • Metformin Discontinuation Rule: Metformin must be discontinued at the time of or prior to iodinated contrast administration and held for 48 hours48\,\text{hours} before and after the procedure; therapy is reinstated only after laboratory confirmation of preserved renal function.

  • Premedication Prophylaxis Regimens

    • For patients presenting with heightened risk profiles or documented prior allergic-like contrast reactions, a premedication protocol using systemic corticosteroids and antihistamines is prescribed to mitigate the incidence and severity of acute allergic-like reactions.

Contrast Media Reactions and Emergency Management

  • Severity Classification of Acute Adverse Reactions

    • Acute reactions to water-soluble iodinated contrast media are categorized according to severity into mild, moderate, or severe tiers.
    • Memory Trick: Mild = limited. Moderate = more pronounced. Severe = breathing, circulation, or consciousness in jeopardy.

  • Mild Reactions

    • Clinical Presentation: Limited cutaneous hives (urticaria), localized mild pruritus, localized mild swelling, paroxysmal sneezing, rhinitis / runny nose, transient nausea, mild vomiting, or transient systemic sensations of warmth and flushing.
    • Clinical Management: Typically requires no active pharmaceutical intervention; observe the patient carefully, provide reassurance, monitor vital signs, and confirm total resolution of symptoms without upward progression.

  • Moderate Reactions

    • Clinical Presentation: Widespread diffuse urticaria, cutaneous erythema, pronounced facial edema without concurrent respiratory compromise, feeling of throat tightness or hoarseness without overt dyspnea, reactive wheezing / mild bronchospasm, persistent intractable vomiting, or symptomatic vasovagal responses requiring active clinical support.
    • Clinical Management: Requires rapid clinical evaluation, direct physician assessment, proactive monitoring, and pharmacological administration of targeted rescue therapeutics (e.g., antihistamines, antiemetics, or bronchodilators) to abort symptoms and prevent progression.

  • Severe Reactions

    • Clinical Presentation: Profound facial, tongue, or laryngeal edema accompanied by respiratory distress; severe dyspnea, refractory bronchospasm, and hypoxia; florid anaphylactic shock; acute hypotension and major cardiac dysrhythmias; non-cardiogenic pulmonary edema; acute grand mal seizures; or full cardiopulmonary arrest.
    • Clinical Management: A medical emergency demanding instantaneous mobilization of life-support teams, discontinuation of the contrast, deployment of emergency code protocols, maintenance of airway patency, high-flow oxygen, and epinephrine delivery.

Radiopharmaceuticals and Molecular Imaging

  • Definition and Mechanics of Radiopharmaceuticals

    • A radiopharmaceutical is an organ-specific pharmaceutical tracer compound chemically tagged or conjugated to a radionuclide (radioisotope).
    • Radiopharmaceuticals differ fundamentally from diagnostic radiographic contrast media: they are not administered to attenuate X-rays, but rather to assess metabolic, physiological, and functional processes.
    • Mechanism of Localization: The biodistribution of a radiopharmaceutical is determined by the specific physiological or biochemical characteristics of the attached pharmaceutical tracer and its affinity for target biological tissues or organ systems.

  • Radiation Detection Systems

    • Gamma Cameras: Detect gamma photons emitted from decaying radionuclides located internally within the patient to construct functional diagnostic planar or SPECT images.
    • Positron Emission Tomography (PET) Physics:
    • Positrons (β+\beta^+) emitted via radionuclide decay travel a millimeter distance before colliding with ambient free electrons (e−e^-) in tissue.
    • The resulting mass-energy annihilation event transforms the rest mass of both particles into two identical high-energy gamma photons, each possessing precisely 511 keV511\,\text{keV}.
    • These two 511 keV511\,\text{keV} annihilation photons travel in nearly opposite directions (separated by approximately 180∘180^\circ).
    • Coincidence detection circuits within the circumferential PET ring register simultaneous photon hits to reconstruct tomographic tracer maps.

  • Radioactive Contamination Considerations

    • Accidental external spills, droplets, or contamination originating from unsealed liquid diagnostic radioisotopes on patient skin, gowns, or detector faces represent a critical imaging hazard.
    • Contaminants create focal zones of intense radionuclide emission that can be misconstrued as severe localized anatomical pathology or skeletal metastasis on the final image.